Trade Larimar Therapeutics, Inc. - LRMR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Larimar Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 3.39 |
Open* | 3.28 |
1-Year Change* | 9.33% |
Day's Range* | 3.28 - 3.54 |
52 wk Range | 2.18-6.85 |
Average Volume (10 days) | 142.76K |
Average Volume (3 months) | 2.41M |
Market Cap | 135.23M |
P/E Ratio | -100.00K |
Shares Outstanding | 43.91M |
Revenue | N/A |
EPS | -0.76 |
Dividend (Yield %) | N/A |
Beta | 0.50 |
Next Earnings Date | Mar 12, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 3.50 | 0.22 | 6.71% | 3.28 | 3.54 | 3.25 |
Nov 30, 2023 | 3.39 | 0.23 | 7.28% | 3.16 | 3.43 | 3.16 |
Nov 29, 2023 | 3.23 | -0.15 | -4.44% | 3.38 | 3.46 | 3.14 |
Nov 28, 2023 | 3.37 | -0.01 | -0.30% | 3.38 | 3.48 | 3.28 |
Nov 27, 2023 | 3.51 | 0.08 | 2.33% | 3.43 | 3.52 | 3.32 |
Nov 24, 2023 | 3.48 | 0.22 | 6.75% | 3.26 | 3.58 | 3.26 |
Nov 22, 2023 | 3.28 | 0.19 | 6.15% | 3.09 | 3.28 | 2.97 |
Nov 21, 2023 | 3.05 | -0.05 | -1.61% | 3.10 | 3.16 | 3.01 |
Nov 20, 2023 | 3.11 | -0.17 | -5.18% | 3.28 | 3.28 | 3.04 |
Nov 17, 2023 | 3.25 | 0.07 | 2.20% | 3.18 | 3.41 | 3.15 |
Nov 16, 2023 | 3.04 | 0.17 | 5.92% | 2.87 | 3.17 | 2.71 |
Nov 15, 2023 | 2.90 | 0.43 | 17.41% | 2.47 | 2.95 | 2.47 |
Nov 14, 2023 | 2.50 | 0.06 | 2.46% | 2.44 | 2.71 | 2.43 |
Nov 13, 2023 | 2.36 | 0.17 | 7.76% | 2.19 | 2.38 | 2.18 |
Nov 10, 2023 | 2.37 | 0.21 | 9.72% | 2.16 | 2.40 | 2.15 |
Nov 9, 2023 | 2.28 | -0.42 | -15.56% | 2.70 | 2.70 | 2.23 |
Nov 8, 2023 | 2.75 | -0.11 | -3.85% | 2.86 | 2.95 | 2.71 |
Nov 7, 2023 | 3.09 | 0.07 | 2.32% | 3.02 | 3.13 | 2.95 |
Nov 6, 2023 | 3.08 | 0.01 | 0.33% | 3.07 | 3.15 | 2.98 |
Nov 3, 2023 | 3.17 | 0.32 | 11.23% | 2.85 | 3.17 | 2.85 |
Larimar Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, March 12, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Larimar Therapeutics Inc Earnings Release Q4 2023 Larimar Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 36.526 | 50.465 | 42.804 | 45.654 | 61.122 |
Selling/General/Admin. Expenses, Total | 12.276 | 12.069 | 11.397 | 16.215 | 13.193 |
Research & Development | 24.25 | 38.396 | 31.407 | 23.886 | 47.929 |
Operating Income | -36.526 | -50.465 | -42.804 | -45.654 | -61.122 |
Interest Income (Expense), Net Non-Operating | 0.248 | -0.246 | |||
Net Income Before Taxes | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Net Income After Taxes | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Net Income Before Extra. Items | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Net Income | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Income Available to Common Incl. Extra. Items | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Diluted Net Income | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Diluted Weighted Average Shares | 25.7614 | 17.1643 | 11.8832 | 3.11227 | 2.68562 |
Diluted EPS Excluding Extraordinary Items | -1.3724 | -2.95008 | -3.57498 | -14.5894 | -22.8506 |
Diluted Normalized EPS | -1.3724 | -2.95008 | -3.57498 | -12.8051 | -22.8506 |
Total Extraordinary Items | |||||
Unusual Expense (Income) | 5.553 | ||||
Other, Net | 1.171 | -0.171 | 0.322 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 9.62 | 7.637 | 10.439 | 8.513 | 8.687 |
Selling/General/Admin. Expenses, Total | 3.745 | 3.075 | 3.221 | 2.931 | 3.043 |
Research & Development | 5.875 | 4.562 | 7.218 | 5.582 | 5.644 |
Operating Income | -9.62 | -7.637 | -10.439 | -8.513 | -8.687 |
Other, Net | 1.254 | 1.111 | 1.014 | 0.193 | 0.02 |
Net Income Before Taxes | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Net Income After Taxes | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Net Income Before Extra. Items | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Net Income | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Income Available to Common Excl. Extra. Items | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Income Available to Common Incl. Extra. Items | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Diluted Net Income | -8.366 | -6.526 | -9.425 | -8.32 | -8.667 |
Diluted Weighted Average Shares | 43.8976 | 43.8976 | 44.0969 | 22.2282 | 18.3389 |
Diluted EPS Excluding Extraordinary Items | -0.19058 | -0.14866 | -0.21373 | -0.3743 | -0.4726 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.19058 | -0.14866 | -0.21373 | -0.3743 | -0.4726 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 120.739 | 72.204 | 97.952 | 71.503 | 121.33 |
Cash and Short Term Investments | 118.428 | 70.097 | 92.638 | 70.261 | 118.066 |
Cash & Equivalents | 26.825 | 70.097 | 68.148 | 27.211 | 49.331 |
Short Term Investments | 91.603 | 0 | 24.49 | 43.05 | 68.735 |
Total Receivables, Net | 0 | 0.208 | 0.243 | 1.536 | |
Prepaid Expenses | 2.311 | 1.899 | 5.314 | 0.999 | 1.728 |
Total Assets | 126.405 | 78.667 | 104.686 | 80.734 | 121.762 |
Property/Plant/Equipment, Total - Net | 3.689 | 4.455 | 4.976 | 7.872 | 0.375 |
Property/Plant/Equipment, Total - Gross | 4.603 | 5.051 | 5.311 | 8.615 | 0.925 |
Accumulated Depreciation, Total | -0.914 | -0.596 | -0.335 | -0.743 | -0.55 |
Other Long Term Assets, Total | 1.977 | 2.008 | 1.758 | 1.359 | 0.057 |
Total Current Liabilities | 10.705 | 8.846 | 8.992 | 12.19 | 13.306 |
Accounts Payable | 1.686 | 1.66 | 2.634 | 0.632 | 3.59 |
Accrued Expenses | 9.019 | 7.186 | 6.358 | 4.285 | 4.261 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7.273 | 5.455 | |||
Total Liabilities | 15.502 | 14.254 | 14.994 | 27.11 | 28.491 |
Total Long Term Debt | 0 | 0 | 0 | 8.464 | 15.185 |
Long Term Debt | 8.464 | 15.185 | |||
Total Equity | 110.903 | 64.413 | 89.692 | 53.624 | 93.271 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.043 | 0.018 | 0.015 | 0.037 | 0.037 |
Additional Paid-In Capital | 262.496 | 180.645 | 155.29 | 449.903 | 444.212 |
Retained Earnings (Accumulated Deficit) | -151.605 | -116.25 | -65.614 | -396.351 | -350.945 |
Other Equity, Total | -0.031 | 0 | 0.001 | 0.035 | -0.033 |
Total Liabilities & Shareholders’ Equity | 126.405 | 78.667 | 104.686 | 80.734 | 121.762 |
Total Common Shares Outstanding | 43.2692 | 17.7104 | 15.3677 | 3.12042 | 3.10714 |
Other Liabilities, Total | 4.797 | 5.408 | 6.002 | 6.456 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 98.48 | 106.478 | 113.464 | 120.739 | 127.127 |
Cash and Short Term Investments | 95.59 | 104.2 | 111.524 | 118.428 | 124.699 |
Cash & Equivalents | 38.721 | 94.321 | 111.524 | 26.825 | 86.047 |
Short Term Investments | 56.869 | 9.879 | 0 | 91.603 | 38.652 |
Prepaid Expenses | 2.89 | 2.278 | 1.94 | 2.311 | 2.314 |
Total Assets | 103.952 | 111.716 | 118.907 | 126.405 | 133.015 |
Property/Plant/Equipment, Total - Net | 3.499 | 3.255 | 3.472 | 3.689 | 3.906 |
Property/Plant/Equipment, Total - Gross | 4.643 | 4.323 | 4.464 | 4.603 | 4.742 |
Accumulated Depreciation, Total | -1.144 | -1.068 | -0.992 | -0.914 | -0.836 |
Other Long Term Assets, Total | 1.973 | 1.983 | 1.971 | 1.977 | 1.982 |
Total Current Liabilities | 6.558 | 7.275 | 8.01 | 10.705 | 9.42 |
Accounts Payable | 0.756 | 2.344 | 0.695 | 1.686 | 0.849 |
Accrued Expenses | 5.802 | 4.931 | 7.315 | 9.019 | 8.571 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11.24 | 11.786 | 12.666 | 15.502 | 14.353 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 4.682 | 4.511 | 4.656 | 4.797 | 4.933 |
Total Equity | 92.712 | 99.93 | 106.241 | 110.903 | 118.662 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.043 | 0.043 | 0.043 | 0.043 | 0.043 |
Additional Paid-In Capital | 268.223 | 266.372 | 264.329 | 262.496 | 260.839 |
Retained Earnings (Accumulated Deficit) | -175.561 | -166.497 | -158.131 | -151.605 | -142.18 |
Other Equity, Total | 0.007 | 0.012 | 0 | -0.031 | -0.04 |
Total Liabilities & Shareholders’ Equity | 103.952 | 111.716 | 118.907 | 126.405 | 133.015 |
Total Common Shares Outstanding | 43.9059 | 43.2692 | 43.2692 | 43.2692 | 43.2692 |
Total Receivables, Net | 0 | 0.114 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -35.355 | -50.636 | -42.482 | -45.406 | -61.368 |
Cash From Operating Activities | -27.569 | -42.105 | -42.199 | -40.783 | -51.487 |
Cash From Operating Activities | 0.318 | 0.326 | 0.155 | 0.263 | 0.261 |
Non-Cash Items | 5.845 | 5.458 | 2.171 | 4.745 | 9.027 |
Cash Interest Paid | 1.217 | 1.144 | |||
Changes in Working Capital | 1.623 | 2.747 | -2.043 | -0.385 | 0.593 |
Cash From Investing Activities | -90.96 | 24.169 | 17.09 | 25.263 | -6.867 |
Capital Expenditures | -0.1 | -0.333 | -0.062 | -0.764 | -0.108 |
Other Investing Cash Flow Items, Total | -90.86 | 24.502 | 17.152 | 26.027 | -6.759 |
Cash From Financing Activities | 75.257 | 19.885 | 93.587 | -5.261 | 66.908 |
Financing Cash Flow Items | 0 | 17.995 | 0 | -0.312 | |
Issuance (Retirement) of Stock, Net | 75.257 | 19.885 | 75.592 | 0.194 | 67.22 |
Issuance (Retirement) of Debt, Net | -5.455 | 0 | |||
Net Change in Cash | -43.272 | 1.949 | 68.478 | -20.781 | 8.554 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.526 | -35.355 | -25.93 | -17.61 | -8.943 |
Cash From Operating Activities | -7.551 | -27.569 | -20.897 | -15.019 | -7.533 |
Cash From Operating Activities | 0.078 | 0.318 | 0.24 | 0.163 | 0.082 |
Non-Cash Items | 1.217 | 5.845 | 4.91 | 3.307 | 1.635 |
Changes in Working Capital | -2.32 | 1.623 | -0.117 | -0.879 | -0.307 |
Cash From Investing Activities | 92.25 | -90.96 | -38.726 | -35.342 | 0 |
Capital Expenditures | -0.1 | -0.1 | -0.1 | ||
Other Investing Cash Flow Items, Total | 92.25 | -90.86 | -38.626 | -35.242 | 0 |
Cash From Financing Activities | 0 | 75.257 | 75.573 | 0 | 0 |
Financing Cash Flow Items | 0 | 0 | 0 | ||
Net Change in Cash | 84.699 | -43.272 | 15.95 | -50.361 | -7.533 |
Issuance (Retirement) of Stock, Net | 75.257 | 75.573 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Deerfield Management Company, L.P. | Hedge Fund | 39.1459 | 16941357 | 0 | 2023-06-30 | MED |
Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 7.8897 | 3414468 | 668203 | 2023-06-30 | HIGH |
Verition Fund Management LLC | Hedge Fund | 6.2774 | 2716713 | 777891 | 2023-06-30 | HIGH |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 5.0636 | 2191411 | 745685 | 2023-08-10 | LOW |
Woodline Partners LP | Hedge Fund | 3.8863 | 1681913 | 0 | 2023-06-30 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.2155 | 1391601 | 100191 | 2023-06-30 | LOW |
Opaleye Management Inc. | Hedge Fund | 3.2118 | 1390000 | -11000 | 2023-06-30 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.0264 | 1309766 | 991499 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.7189 | 1176655 | 500217 | 2023-06-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 1.9387 | 839000 | 384000 | 2023-06-30 | HIGH |
Mangrove Partners | Hedge Fund | 1.862 | 805815 | 0 | 2023-06-30 | MED |
Adage Capital Management, L.P. | Hedge Fund | 1.5058 | 651680 | 0 | 2023-06-30 | LOW |
Hamilton (Thomas Edward) | Individual Investor | 1.4102 | 610313 | 0 | 2023-03-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2398 | 536560 | 264596 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9943 | 430317 | 324114 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.9371 | 405541 | -52478 | 2023-06-30 | HIGH |
UBS O'Connor LLC | Hedge Fund | 0.8399 | 363505 | 151011 | 2023-06-30 | HIGH |
Dafna Capital Management, LLC | Hedge Fund | 0.8096 | 350373 | 113500 | 2023-06-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7369 | 318909 | 153467 | 2023-06-30 | LOW |
Atlas Venture | Venture Capital | 0.6751 | 292184 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Larimar Therapeutics, Inc. Company profile
About Larimar Therapeutics Inc
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Larimar Therapeutics Inc revenues was not reported. Net loss increased 47% to $41.5M. Higher net loss reflects Research and Development increase of 50% to $30.6M (expense), Stock-based Compensation in SGA increase from $709K to $2.5M (expense), Stock-based Compensation in R&D increase from $442K to $1.5M (expense).
Equity composition
Common Stock, $0.001 Par, 06/14, auth. 115M shares,. 20,807,012 issd,. Insiders owns approx. 28.83%.
Industry: | Bio Therapeutic Drugs |
Three Bala Plaza East. Suite 506
BALA CYNWYD
PENNSYLVANIA 19004
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com